![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LOXL4 |
Gene summary for LOXL4 |
![]() |
Gene information | Species | Human | Gene symbol | LOXL4 | Gene ID | 84171 |
Gene name | lysyl oxidase like 4 | |
Gene Alias | LOXC | |
Cytomap | 10q24.2 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q96JB6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84171 | LOXL4 | LZE4T | Human | Esophagus | ESCC | 8.55e-04 | 7.04e-02 | 0.0811 |
84171 | LOXL4 | P8T-E | Human | Esophagus | ESCC | 2.30e-13 | 2.41e-01 | 0.0889 |
84171 | LOXL4 | P9T-E | Human | Esophagus | ESCC | 4.41e-03 | 7.97e-02 | 0.1131 |
84171 | LOXL4 | P10T-E | Human | Esophagus | ESCC | 4.86e-11 | 2.49e-01 | 0.116 |
84171 | LOXL4 | P12T-E | Human | Esophagus | ESCC | 6.68e-13 | 4.03e-01 | 0.1122 |
84171 | LOXL4 | P16T-E | Human | Esophagus | ESCC | 5.55e-22 | 4.98e-01 | 0.1153 |
84171 | LOXL4 | P30T-E | Human | Esophagus | ESCC | 1.51e-04 | 3.72e-01 | 0.137 |
84171 | LOXL4 | P31T-E | Human | Esophagus | ESCC | 3.80e-39 | 7.37e-01 | 0.1251 |
84171 | LOXL4 | P32T-E | Human | Esophagus | ESCC | 4.96e-02 | -1.90e-02 | 0.1666 |
84171 | LOXL4 | P42T-E | Human | Esophagus | ESCC | 6.06e-07 | 4.66e-02 | 0.1175 |
84171 | LOXL4 | P47T-E | Human | Esophagus | ESCC | 1.26e-06 | 2.83e-01 | 0.1067 |
84171 | LOXL4 | P57T-E | Human | Esophagus | ESCC | 3.69e-16 | 8.92e-01 | 0.0926 |
84171 | LOXL4 | P61T-E | Human | Esophagus | ESCC | 1.76e-02 | 2.78e-02 | 0.099 |
84171 | LOXL4 | P62T-E | Human | Esophagus | ESCC | 4.07e-05 | 5.34e-01 | 0.1302 |
84171 | LOXL4 | P76T-E | Human | Esophagus | ESCC | 1.95e-21 | 6.74e-01 | 0.1207 |
84171 | LOXL4 | C38 | Human | Oral cavity | OSCC | 2.88e-03 | 3.11e-01 | 0.172 |
84171 | LOXL4 | C06 | Human | Oral cavity | OSCC | 4.85e-06 | 1.24e+00 | 0.2699 |
84171 | LOXL4 | C08 | Human | Oral cavity | OSCC | 5.27e-33 | 1.13e+00 | 0.1919 |
84171 | LOXL4 | SYSMH1 | Human | Oral cavity | OSCC | 9.25e-09 | 2.03e-01 | 0.1127 |
84171 | LOXL4 | SYSMH6 | Human | Oral cavity | OSCC | 9.26e-07 | 1.62e-01 | 0.1275 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
GO:00301993 | Esophagus | ESCC | collagen fibril organization | 40/8552 | 61/18723 | 1.35e-03 | 6.44e-03 | 40 |
GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
GO:00301983 | Oral cavity | OSCC | extracellular matrix organization | 146/7305 | 301/18723 | 4.67e-04 | 2.77e-03 | 146 |
GO:00452293 | Oral cavity | OSCC | external encapsulating structure organization | 147/7305 | 304/18723 | 5.30e-04 | 3.08e-03 | 147 |
GO:00430623 | Oral cavity | OSCC | extracellular structure organization | 146/7305 | 302/18723 | 5.59e-04 | 3.23e-03 | 146 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LOXL4 | SNV | Missense_Mutation | novel | c.1550A>G | p.His517Arg | p.H517R | Q96JB6 | protein_coding | tolerated(1) | benign(0.012) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
LOXL4 | SNV | Missense_Mutation | novel | c.594N>G | p.Asn198Lys | p.N198K | Q96JB6 | protein_coding | tolerated(1) | probably_damaging(0.936) | TCGA-EO-A22S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LOXL4 | SNV | Missense_Mutation | rs150077126 | c.1280N>A | p.Arg427His | p.R427H | Q96JB6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LOXL4 | SNV | Missense_Mutation | rs151082276 | c.301N>T | p.Arg101Cys | p.R101C | Q96JB6 | protein_coding | deleterious(0.05) | probably_damaging(0.93) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LOXL4 | insertion | Frame_Shift_Ins | novel | c.1962_1963insATTGCAGCGG | p.Arg655IlefsTer26 | p.R655Ifs*26 | Q96JB6 | protein_coding | TCGA-EO-A3L0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
LOXL4 | SNV | Missense_Mutation | rs375427147 | c.1652N>A | p.Arg551His | p.R551H | Q96JB6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BD-A3EP-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LOXL4 | SNV | Missense_Mutation | rs377758453 | c.407N>A | p.Arg136His | p.R136H | Q96JB6 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-CC-A5UE-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
LOXL4 | SNV | Missense_Mutation | novel | c.1658T>A | p.Leu553His | p.L553H | Q96JB6 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-DD-AAE9-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LOXL4 | SNV | Missense_Mutation | c.1172N>A | p.Pro391His | p.P391H | Q96JB6 | protein_coding | tolerated(0.28) | benign(0.007) | TCGA-44-2656-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
LOXL4 | SNV | Missense_Mutation | novel | c.1454N>A | p.Pro485Gln | p.P485Q | Q96JB6 | protein_coding | tolerated(0.54) | probably_damaging(0.922) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |